AU2014209466B2 - Dosage forms and therapeutic uses L-4-chlorokynurenine - Google Patents

Dosage forms and therapeutic uses L-4-chlorokynurenine Download PDF

Info

Publication number
AU2014209466B2
AU2014209466B2 AU2014209466A AU2014209466A AU2014209466B2 AU 2014209466 B2 AU2014209466 B2 AU 2014209466B2 AU 2014209466 A AU2014209466 A AU 2014209466A AU 2014209466 A AU2014209466 A AU 2014209466A AU 2014209466 B2 AU2014209466 B2 AU 2014209466B2
Authority
AU
Australia
Prior art keywords
chlorokynurenine
days
administered
pain
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014209466A
Other languages
English (en)
Other versions
AU2014209466A1 (en
Inventor
Allen E. Cato
Jack S. Hicklin
H. Ralph Snodgrass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vistagen Therapeutics Inc
Original Assignee
Vistagen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vistagen Therapeutics Inc filed Critical Vistagen Therapeutics Inc
Publication of AU2014209466A1 publication Critical patent/AU2014209466A1/en
Priority to AU2018253600A priority Critical patent/AU2018253600B2/en
Application granted granted Critical
Publication of AU2014209466B2 publication Critical patent/AU2014209466B2/en
Priority to AU2020204420A priority patent/AU2020204420A1/en
Priority to AU2022221382A priority patent/AU2022221382B2/en
Priority to AU2024278564A priority patent/AU2024278564A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Lubricants (AREA)
  • Quinoline Compounds (AREA)
AU2014209466A 2013-01-22 2014-01-22 Dosage forms and therapeutic uses L-4-chlorokynurenine Active AU2014209466B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2018253600A AU2018253600B2 (en) 2013-01-22 2018-10-26 Dosage forms and therapeutic uses of l-4-chlorokynurenine
AU2020204420A AU2020204420A1 (en) 2013-01-22 2020-07-01 Dosage forms and therapeutic uses of l-4-chlorokynurenine
AU2022221382A AU2022221382B2 (en) 2013-01-22 2022-08-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine
AU2024278564A AU2024278564A1 (en) 2013-01-22 2024-12-18 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361849191P 2013-01-22 2013-01-22
US61/849,191 2013-01-22
PCT/US2014/012598 WO2014116739A1 (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses l-4-chlorokynurenine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018253600A Division AU2018253600B2 (en) 2013-01-22 2018-10-26 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Publications (2)

Publication Number Publication Date
AU2014209466A1 AU2014209466A1 (en) 2015-08-06
AU2014209466B2 true AU2014209466B2 (en) 2018-11-08

Family

ID=51228003

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2014209466A Active AU2014209466B2 (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses L-4-chlorokynurenine
AU2018253600A Active AU2018253600B2 (en) 2013-01-22 2018-10-26 Dosage forms and therapeutic uses of l-4-chlorokynurenine
AU2020204420A Abandoned AU2020204420A1 (en) 2013-01-22 2020-07-01 Dosage forms and therapeutic uses of l-4-chlorokynurenine
AU2022221382A Active AU2022221382B2 (en) 2013-01-22 2022-08-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine
AU2024278564A Pending AU2024278564A1 (en) 2013-01-22 2024-12-18 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2018253600A Active AU2018253600B2 (en) 2013-01-22 2018-10-26 Dosage forms and therapeutic uses of l-4-chlorokynurenine
AU2020204420A Abandoned AU2020204420A1 (en) 2013-01-22 2020-07-01 Dosage forms and therapeutic uses of l-4-chlorokynurenine
AU2022221382A Active AU2022221382B2 (en) 2013-01-22 2022-08-22 Dosage forms and therapeutic uses of l-4-chlorokynurenine
AU2024278564A Pending AU2024278564A1 (en) 2013-01-22 2024-12-18 Dosage forms and therapeutic uses of l-4-chlorokynurenine

Country Status (22)

Country Link
US (8) US9993450B2 (enExample)
EP (4) EP3228313B1 (enExample)
JP (5) JP6436913B2 (enExample)
KR (5) KR20230003410A (enExample)
CN (4) CN113209068A (enExample)
AU (5) AU2014209466B2 (enExample)
BR (1) BR112015017535A2 (enExample)
CA (3) CA3216579A1 (enExample)
CY (1) CY1122403T1 (enExample)
DK (3) DK3598971T3 (enExample)
ES (3) ES2980120T3 (enExample)
HK (1) HK1217170A1 (enExample)
HR (2) HRP20240812T1 (enExample)
HU (1) HUE067381T2 (enExample)
IL (3) IL240090B (enExample)
MX (2) MX375318B (enExample)
PL (2) PL3598971T3 (enExample)
PT (3) PT3228313T (enExample)
RS (1) RS59687B1 (enExample)
SI (2) SI3598971T1 (enExample)
WO (1) WO2014116739A1 (enExample)
ZA (2) ZA201505569B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3216579A1 (en) 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
DK3297619T3 (da) * 2015-05-22 2022-08-15 Vistagen Therapeutics Inc Terapeutiske anvendelser af L-4-chlorkynurenin
WO2017044516A1 (en) * 2015-09-08 2017-03-16 Cephalon, Inc. Prodrugs of chlorokynurenines
CN112236412B (zh) 2018-02-09 2024-01-30 维斯塔津治疗公司 4-氯代犬尿氨酸及中间体的合成
CN109223785A (zh) * 2018-10-29 2019-01-18 中国药科大学 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用
WO2022082100A1 (en) * 2020-10-16 2022-04-21 Vistagen Therapeutics, Inc. Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5360814A (en) 1991-02-28 1994-11-01 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
US5484814A (en) * 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
CA2457011C (en) 2001-08-20 2012-04-24 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
JP2006502158A (ja) 2002-09-06 2006-01-19 デュレクト コーポレーション グルタメート媒介神経伝達のモジュレーターの内耳への送達
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
AU2007235876A1 (en) 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
EP1903028A1 (en) * 2006-09-22 2008-03-26 Werner Tschollar Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009135091A1 (en) * 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
CN102159077A (zh) * 2008-08-21 2011-08-17 吉瑞工厂 用于治疗神经性疼痛的方法
PT2421519T (pt) 2009-04-23 2017-01-26 Univ Zuerich Bloqueadores do recetor nmda para o tratamento de anemia falciforme
RU2012101424A (ru) * 2009-06-17 2013-07-27 Таргасепт, Инк. Устранение l-дофа-индуцированной дискинезии с помощью лигандов нейрональных никотиновых рецепторов
JPWO2011019072A1 (ja) 2009-08-12 2013-01-17 ヒューマン・メタボローム・テクノロジーズ株式会社 うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP2338873A1 (en) * 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CA3216579A1 (en) 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
JP2016513718A (ja) 2013-03-14 2016-05-16 ヴィスタゲン セラピューティクス、インコーポレイテッド キラルキヌレニン化合物及び中間体の合成
US9745342B2 (en) 2013-10-28 2017-08-29 Naurex, Inc. NMDA receptor modulators and prodrugs, salts, and uses thereof
DK3297619T3 (da) 2015-05-22 2022-08-15 Vistagen Therapeutics Inc Terapeutiske anvendelser af L-4-chlorkynurenin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers", CinicalTrials.gov, Identifier: NCT01483846, Available from the Internet, <URL: https://clinicaltrials.gov/ct2/show/NCT01483846> *
WU H. ET AL., "Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus", EUROPEAN JOURNAL OF PHARMACOLOGY, (2000), vol. 390, pages 267 -274 *

Also Published As

Publication number Publication date
PT3228313T (pt) 2019-12-17
JP2016505050A (ja) 2016-02-18
IL240090A0 (en) 2015-09-24
CA3128321C (en) 2023-12-05
AU2018253600A1 (en) 2018-11-22
KR102335919B1 (ko) 2021-12-07
DK2948140T3 (en) 2017-08-21
JP2019023195A (ja) 2019-02-14
JP6804497B2 (ja) 2020-12-23
MX375318B (es) 2025-03-06
DK3228313T3 (da) 2019-11-25
IL291831A (en) 2022-06-01
CA2898619A1 (en) 2014-07-31
US20180289649A1 (en) 2018-10-11
CY1122403T1 (el) 2021-01-27
US10632091B2 (en) 2020-04-28
ES2635353T3 (es) 2017-10-03
US9993450B2 (en) 2018-06-12
AU2022221382B2 (en) 2024-09-19
JP2022070894A (ja) 2022-05-13
US20150359772A1 (en) 2015-12-17
US9993453B2 (en) 2018-06-12
US20190125707A1 (en) 2019-05-02
EP2948140B1 (en) 2017-05-10
EP4385563A3 (en) 2024-08-21
PL3598971T3 (pl) 2024-09-09
HK1217170A1 (zh) 2016-12-30
US20180369180A1 (en) 2018-12-27
EP4385563A2 (en) 2024-06-19
SI3598971T1 (sl) 2024-10-30
DK3598971T3 (da) 2024-06-10
ES2751138T3 (es) 2020-03-30
EP3598971A1 (en) 2020-01-29
KR20210063449A (ko) 2021-06-01
US20250161251A1 (en) 2025-05-22
CN113116877A (zh) 2021-07-16
JP7021298B2 (ja) 2022-02-16
US20220409564A1 (en) 2022-12-29
IL276126A (en) 2020-08-31
KR20230003410A (ko) 2023-01-05
MX2020009966A (es) 2020-10-12
CA3128321A1 (en) 2014-07-31
IL240090B (en) 2020-08-31
KR20230098711A (ko) 2023-07-04
ZA201505569B (en) 2017-01-25
MX2015009277A (es) 2015-12-11
CN113209068A (zh) 2021-08-06
CA3216579A1 (en) 2014-07-31
IL291831B2 (en) 2026-08-01
US20160158178A1 (en) 2016-06-09
EP3228313B1 (en) 2019-09-11
PT2948140T (pt) 2017-08-10
AU2022221382A1 (en) 2022-09-15
PL3228313T3 (pl) 2020-03-31
US20190133984A1 (en) 2019-05-09
WO2014116739A1 (en) 2014-07-31
KR20210149905A (ko) 2021-12-09
JP2024069257A (ja) 2024-05-21
IL276126B (en) 2022-05-01
HRP20192189T1 (hr) 2020-02-21
ES2980120T3 (es) 2024-09-30
KR102257284B1 (ko) 2021-05-28
PT3598971T (pt) 2024-06-20
CN105073108A (zh) 2015-11-18
JP6436913B2 (ja) 2018-12-12
CN112933073A (zh) 2021-06-11
BR112015017535A2 (pt) 2020-02-04
KR20150109428A (ko) 2015-10-01
US10617663B2 (en) 2020-04-14
AU2018253600B2 (en) 2020-07-09
RS59687B1 (sr) 2020-01-31
CA2898619C (en) 2021-10-19
AU2014209466A1 (en) 2015-08-06
US10980758B2 (en) 2021-04-20
EP2948140A4 (en) 2016-08-03
ZA201607581B (en) 2019-04-24
AU2024278564A1 (en) 2025-01-09
EP3598971B1 (en) 2024-03-20
IL291831B1 (en) 2026-04-01
SI3228313T1 (sl) 2019-12-31
EP2948140A1 (en) 2015-12-02
JP2020183400A (ja) 2020-11-12
HUE067381T2 (hu) 2024-10-28
HRP20240812T1 (hr) 2024-09-27
AU2020204420A1 (en) 2020-07-23
EP3228313A1 (en) 2017-10-11
US12036198B2 (en) 2024-07-16
NZ710121A (en) 2021-01-29

Similar Documents

Publication Publication Date Title
AU2022221382B2 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
HK40022228A (en) Dosage forms and therapeutic uses l-4- chlorokynurenine
HK40022228B (en) Dosage forms and therapeutic uses l-4- chlorokynurenine
HK40059702A (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
HK40054519A (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
NZ710121B2 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)